Related Experiment Video
Updated: May 28, 2026
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Recent advances in the understanding of Langerhans cell histiocytosis
Gayane Badalian-Very1, Jo-Anne Vergilio, Barbara A Degar
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Insights
Langerhans cell histiocytosis (LCH) is now understood as a myeloid neoplasm, not originating from epidermal Langerhans cells. Activating BRAF mutations are common, paving the way for targeted therapies.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- Langerhans cell histiocytosis (LCH) is a rare proliferative disorder with variable clinical presentations.
- The precise cell of origin and pathogenesis of LCH have remained largely unclear.
- Previous understanding linked LCH to epidermal Langerhans cells (LCs).
Purpose of the Study:
- To elucidate the cellular origin and molecular underpinnings of Langerhans cell histiocytosis.
- To investigate the role of genetic mutations in LCH pathogenesis.
- To re-evaluate the classification of LCH based on new molecular evidence.
Main Methods:
- Molecular analyses of human LCH samples and mouse models.
- Advanced genomic technologies to detect somatic mutations.
- Phenotypic characterization of LCH cells.
Main Results:
- Evidence suggests LCH originates from myeloid-derived precursors, not epidermal LCs.
- Activating BRAF mutations were identified in the majority of patient specimens.
- These findings support a new classification of LCH as a myeloid neoplasm.
Conclusions:
- Langerhans cell histiocytosis is a myeloid neoplasm driven by somatic BRAF mutations.
- The revised understanding of LCH origin and genetics has significant therapeutic implications.
- Targeted therapies are a promising future direction for LCH treatment.
Abstract:
Langerhans cell histiocytosis (LCH) is a proliferative disease of cells that share phenotypic characteristics with the primary antigen presenting cells of the epidermis. Its clinical manifestations are highly variable, extending from very benign forms to a disseminated, aggressive disease that causes significant mortality. Although many of the fundamental pathogenetic features of LCH have been enigmatic, recent advances have led to a much clearer understanding of the disease. In particular, careful molecular analyses of mouse models and human LCH samples suggest that LCH's cell of origin may not be the epidermal LC itself but a myeloid-derived precursor. Advanced genomic technologies have revealed the presence of activating, somatic BRAF mutations in the majority of patient specimens. Together, these observations have produced a new picture of LCH as a myeloid neoplasm. These advances are likely to have profound implications for the use of targeted therapeutics in LCH.
